RIGL

Rigel Pharmaceuticals Inc. (New) Nasdaq Global Select
$1.07
Open: $1.05 High: $1.13 Low: $1.02 Close: $1.02
Range: 2022-06-27 - 2022-06-28
Volume:150,837
Market: Open
RIGL
Rigel Pharmaceuticals Inc. (New) 1180 VETERANS BOULEVARD https://www.rigel.com
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
  • CEO: Raul R. Rodriguez
  • Employees: 165
  • Sector: Healthcare
  • Industry: Biotechnology
Latest Stocks Posts
Card image
Card image
Card image
RIGL News
Latest news about the RIGL